 Consideration of Cardiovascular Risk and Management in T2DM patient: The Role of Vildagliptin | |
| 協辦單位 | Novartis |
| 上課日期時間 | 108年04月19日（星期五）12:30~14:30 |
| 上課地點 | 高雄市立岡山醫院（委託秀傳醫療社團法人經營） 地下一樓會議室 |
| 報名截止日期 | 2019/04/03 |
| 講師 | 周劍文／周劍文診所、內科、新陳代謝科 |
| 課程大綱 | People with Type 2 diabetes mellitus (T2DM), compared with non-diabetic individuals, have increased cardiovascular risk. Part of this excess risk is associated with a higher prevalence of other cardiovascular risk factors in these patients, such as obesity, dyslipidaemia, and hypertension. However, the increased cardiovascular risk present in T2DM cannot be attributed entirely to the high prevalence of traditional risk factors and other non-traditional risk factors may also be important for people with T2DM.Cardiovascular disease and heart failure are major causes of morbidity and mortality in people with type 2 diabetes. Once heart failure is present in people with diabetes, mortality is increased 10-fold and five year survival is only 12.5%. From 2016 BMJ Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care with gliptin show long term safety and cv risk reduction.A meta-analysis the finding of a significant risk reduction in the incidence of MACE with vildagliptin in the subgroup of patients aged < 65 years is intriguing since none of the CV outcome studies with the DPP-4 inhibitors suggested such potential benefit. |
| 積分 | 西醫師繼續教育積分-醫學課程、內科、家醫科、 護理師／士積分 |